Neuraxpharm expands into the Netherlands

The CNS specialist continues its strong expansion course in Europe and increases its presence from two to 20 countries in just six years

Naarden and Düsseldorf – December 7, 2022 – Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, announces the establishment of Neuraxpharm Netherlands. The expansion into the Dutch market allows Neuraxpharm to continue on its pathway to become the number one CNS specialist in Europe.

Read more…